Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.

ABSTRACT:

Background

Thrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with Covid-19.

Methods

In this open-label, adaptive, multiplatform, controlled trial, we randomly assigned patients who were hospitalized with Covid-19 and who were not critically ill (which was defined as an absence of critical care-level organ support at enrollment) to receive pragmatically defined regimens of either therapeutic-dose anticoagulation with heparin or usual-care pharmacologic thromboprophylaxis. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined i

SUBMITTER: ATTACC Investigators 

PROVIDER: S-EPMC8362594 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature